Send me real-time posts from this site at my email

Watchlist Update Oct 11 : HZNP - Horizon Pharma - Analyst Comments

TIGER'S TAKE:   On our trading list. A good longer term biotech/drug stock. Due to its volatility, options trading around a position can be profitable.   $HZNP

Piper Jaffray rheumatologist survey favorable for Horizon Pharma

Piper Jaffray analyst David Amsellem says his survey of 25 rheumatologists who are current users of Horizon Pharma's Krystexxa in patients with chronic refractory gout reinforced his view that the rheumatology community's view of the risk/benefit profile of the product "continues to evolve considerably, pointing to greater usage among existing Krystexxa users." The feedback also bodes well for usage of the product among practices that are relatively new to Krystexxa, Amsellem tells investors in a research note. He continues to believe that the combination of "continued aggressive" Krystexxa growth along with contribution from teprotumumab starting next year points to a longer term annual EBITDA growth for Horizon "at least in the high-teens." Amsellem keeps an Overweight rating on the shares with a $33 price target.
Source: (

$HZNP, Horizon Therapeutics Public Limited Company / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so).

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue